Surmodics, Inc. (NASDAQ:SRDX), a provider of medical device and in vitro diagnostic technologies to the healthcare industry, today provided the following statement in response to the U.S. Federal Trade Commission's ("FTC" or the "Agency") announcement that it will challenge the proposed acquisition of Surmodics (the "Merger") by funds affiliated with GTCR LLC ("GTCR"), which have an equity investment in Biocoat Inc., a maker of medical coatings: "Surmodics respectfully disagrees with the FTC's decision and remains committed to completing the Merger. Surmodics remains confident in both its rationale for the Merger and the value it will bring to all stakeholders, including shareholders, cust

With the addition of the Pounce™ XL Thrombectomy System, indicated for use in 5.5–10 mm peripheral arteries, the Pounce™ Thrombectomy Platform can now rapidly remove acute or chronic clot throughout the lower extremity without aspiration, thrombolysis, or capital equipment. Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced the successful early clinical use of its Pounce™ XL Thrombectomy System. The Pounce XL Thrombectomy System received U.S. Food and Drug Administration (FDA) 510(k) clearance in September 2024, and is currently in limited market release (LMR), with full commercial launch pl

Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its first quarter ended December 31, 2024. First Quarter Fiscal 2025 Financial Summary Total Revenue of $29.9 million, a decrease of 2% year-over-year Total Revenue excluding SurVeil™ drug-coated balloon ("DCB") license fee revenue(1) of $28.7 million, a decrease of 3% year-over-year GAAP net loss of $(3.7) million, compared to $(0.8) million in the prior-year period Adjusted EBITDA(2) of $3.6 million, compared to $3.9 million in the prior-year period First Quarter and Recent Business Highlights On May 2

Lake Street upgraded Surmodics from Hold to Buy and set a new price target of $43.00

Needham upgraded Surmodics from Hold to Buy and set a new price target of $36.00

Needham downgraded Surmodics from Buy to Hold

4 - SURMODICS INC (0000924717) (Issuer)

4 - SURMODICS INC (0000924717) (Issuer)

4 - SURMODICS INC (0000924717) (Issuer)

8-K - SURMODICS INC (0000924717) (Filer)

SCHEDULE 13G - SURMODICS INC (0000924717) (Subject)

8-K - SURMODICS INC (0000924717) (Filer)

KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty subcutaneous infusion solutions that improve quality of life for patients, today announced the appointment of Andrew D. C. LaFrence as its Chief Financial Officer, effective July 10, 2023. Andy LaFrence joins KORU Medical bringing over 39 years of finance and accounting experience, including a track record of successfully executing and influencing growth-oriented business and M&A strategies, scaling businesses, developing and managing a global team of finance and accounting

Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its first quarter ended December 31, 2024. First Quarter Fiscal 2025 Financial Summary Total Revenue of $29.9 million, a decrease of 2% year-over-year Total Revenue excluding SurVeil™ drug-coated balloon ("DCB") license fee revenue(1) of $28.7 million, a decrease of 3% year-over-year GAAP net loss of $(3.7) million, compared to $(0.8) million in the prior-year period Adjusted EBITDA(2) of $3.6 million, compared to $3.9 million in the prior-year period First Quarter and Recent Business Highlights On May 2

Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its fourth quarter and fiscal year ended September 30, 2024. Fourth Quarter Fiscal 2024 Financial Summary Total Revenue of $33.2 million, an increase of 19% year-over-year Total Revenue excluding SurVeil™ drug-coated balloon ("DCB") license fee revenue(1) of $31.3 million, an increase of 17% year-over-year GAAP net loss of $(3.4) million, compared to net income of $6.7 million in the prior-year period Adjusted EBITDA(2) of $4.4 million, compared to $1.7 million in the prior-year period Fiscal 2024 Financial Summa

Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its third quarter ended June 30, 2024. Third Quarter Fiscal 2024 Financial Summary Total Revenue of $30.3 million, compared to $52.5 million in the prior-year period which included $24.6 million in license fee revenue recognized upon receipt of a $27.0 million milestone payment associated with obtaining FDA premarket approval of the SurVeil™ drug-coated balloon ("DCB") Total Revenue excluding SurVeil DCB license fee revenue(1) of $29.2 million, an increase of 10% year-over-year GAAP net loss of $(7.6) million, co

SC 13G/A - SURMODICS INC (0000924717) (Subject)

SC 13G/A - SURMODICS INC (0000924717) (Subject)

SC 13G/A - SURMODICS INC (0000924717) (Subject)